Spyre Therapeutics Inc. (SYRE) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Spyre Therapeutics Inc. (SYRE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

20.77

-0.78 (-3.62%)

At close: Jan 14, 2025, 3:59 PM

20.80

0.14%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	16.35
Market Cap	1.22B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-37.9
PE Ratio (ttm)	-0.55
Forward PE	n/a
Analyst	Buy

Ask	29.85
Volume	414,728
Avg. Volume (20D)	560,165
Open	21.76
Previous Close	21.55
Day's Range	20.36 - 21.97
52-Week Range	20.07 - 47.97
Beta	undefined

About SYRE

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates desig...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 7, 2016

Employees 30

Stock Exchange NASDAQ

Ticker Symbol SYRE

Website https://www.spyre.com

Analyst Forecast

According to 8 analyst ratings, the average rating for SYRE stock is "Buy." The 12-month stock price forecast is $49.5, which is an increase of 138.32% from the latest price.

Buy 87.50%

Hold 12.50%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Spyre Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of $3.50M, reflecting a n/a YoY growth and earnings per share of -0.76, making a -81.23% decrease YoY.

Why Price Moved

2 months ago · Source

-8.97%

Spyre Therapeutics shares are trading lower. The c... Unlock content with Pro Subscription

10 months ago · Source

-11.68%

Spyre Therapeutics shares are trading lower after the company announced a $180 million private placement of its Series B non-voting convertible preferred stocks at a price of $1,480 per share.

News

4 weeks ago · https://thefly.com

TD says Spyre has 'superior TL1A program' after Teva data

TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to i...

4 weeks ago · https://thefly.com

Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG

BTIG analyst Julian Harrison notes that Teva's (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that "they only own 50% rights to" plus $1B in dev...